Intellia Therapeutics (NTLA) Stock Analysis & AI Equity Report
Intellia Therapeutics (NTLA) overview
Intellia Therapeutics (NTLA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 67.7m and operating profit of USD -441m; the year-end share price was 8.99 USD and market capitalisation was USD 1,046m. Intellia Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Intellia Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Intellia Therapeutics
Intellia Therapeutics is a biopharmaceutical company developing treatments using CRISPR gene editing and related technologies. Its lead candidates are lonvoguran ziclumeran for hereditary angioedema and nexiguran ziclumeran for transthyretin amyloidosis. The company also advances other clinical and preclinical candidates independently and with collaborators, applying gene editing, oligonucleotides, and lipid nanoparticles to develop treatments for severe diseases.
Generate the Intellia Therapeutics report
Intellia Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Intellia Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Intellia Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.